Previous studies have demonstrated that gene editing is feasible in CD34+ cells from patients with hematological disorders such as SCID‐X1 (Genovese et al, 2014) or chronic granulomatous disease (CGD) (De Ravin et al, 2016). This evidence concerns the gene CD34 and hematologic disorder.